🔓
Sign in as a Member to unlock the full view of HR.2831. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$29.99/mo already a Member? Sign in →
HR.2831 · 117TH CONGRESS

Prompt Approval of Safe Generic Drugs Act

Status
Dead
Official Source
Investability
43/100
Stage
COMMITTEE
Related Bills
1
Full Text
2,642 chars
Alive
No

What This Bill Does · Plain English

Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.

Frequently Asked Questions

Did HR.2831 pass?
HR.2831 did not pass and is no longer active. Final stage: COMMITTEE.

Full Bill Text

117 HR 2831 IH: Prompt Approval of Safe Generic Drugs Act U.S. House of Representatives 2021-04-26 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 117th CONGRESS 1st Session H. R. 2831 IN THE HOUSE OF REPRESENTATIVES April 26, 2021 Ms. Barragán introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes. 1. Short title This Act may be cited as the Prompt Approval of Safe Generic Drugs Act . 2. Heading Section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) is amended by adding at the end the following: (z) Prompt approval of drugs when safety information is added to labeling (1) General rule A drug for which an application has been submitted or approved under subsection (b)(2) or (j) shall not be considered ineligible for approval under this section or misbranded under section 502 on the basis that the labeling of the drug omits safety information, including contraindications, warnings, precautions, dosing, administration, or other information pertaining to safety, when the omitted safety information is protected by exclusivity under clause (iii) or (iv) of subsection (c)(3)(E), clause (iii) or (iv) of subsection (j)(5)(F), or section 527(a), or by an extension of such exclusivity under section 505A or 505E. (2) Labeling Notwithstanding clauses (iii) and (iv) of subsection (c)(3)(E), clauses (iii) and (iv) of subsection (j)(5)(F), or section 527, the Secretary shall require that the labeling of a drug approved pursuant to an application submitted under subsection (b)(2) or (j) that omits safety information described in paragraph (1) include a statement of any appropriate safety information that the Secretary considers necessary to assure safe use. (3) Availability and scope of exclusivity This subsection does not affect— (A) the availability or scope of exclusivity or an extension of exclusivity described in subparagraph (A) or (B) of section 505A(o)(3); (B) the question of the eligibility for approval under this section of any application described in subsection (b)(2) or (j) that omits any other aspect of labeling protected by exclusivity under— (i) clause (iii) or (iv) of subsection (c)(3)(E); (ii) clause (iii) or (iv) of subsection (j)(5)(F); or (iii) section 527(a); or (C) except as expressly provided in paragraphs (1) and (2), the operation of this section or section 527. .
🔒 GovGreed Pro · Trading Intelligence on HR.2831 Get Access — $29.99/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-11-17. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]